mRNA Vaccines

mRNA VaccinesPeter A. Jensen2024-05-17T11:32:52+00:00

mRNA vaccine technology is a transformative new sector of the biopharmaceutical industry which has revolutionized vaccine development through increased speed, safety and cost-effective development leading to the first approved vaccines for the COVID-19 pandemic.

mRNA technology allows researchers to fast-track the early stages of vaccine research and development and to produce vaccines faster and more efficiently.

How does an mRNA Vaccine work?

mRNA (messenger RNA) instructs the body to produce proteins which can treat or prevent disease or infections. mRNA vaccines are mRNA molecules that are packaged (encapsulated) in lipid nanoparticles and delivered directly into cells to make proteins to treat or prevent disease or infections by pathogens such as SARS-CoV-2 and emerging “Variants of Concern”.

Fundamental biology of life

DNA (deoxyribonucleic acid) is a double-stranded molecule that stores the genetic instructions for all life on earth. DNA enables the body’s cells to make proteins via RNA (ribonucleic acid) which is derived naturally from DNA. Nearly every function in the body – both normal and disease-related – is a result of one or more proteins.

mRNA enables expression of DNA into proteins

mRNA enables the genetic code of DNA to be used naturally in a process known as protein synthesis. mRNA is the single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to the ribosome, which is the center of protein synthesis in the cell.

How mRNA enables protein synthesis

mRNA Transcription.

A copy of a DNA sequence is generated naturally into mRNA. The mRNA migrates from the nucleus of the cell to the cytoplasm, which houses ribosomes.

The Ribosome.

Nature’s factory in the cell that is responsible for making proteins from mRNA.

mRNA Translation.

The ribosome translates the mRNA into a protein with amino acids which are the building blocks of protein.

Protein Function.

The expressed protein functions in the cell or the body, naturally.

Pricing

Our mission is to enable the large-scale production of highly affordable mRNA vaccines for the people and with a great return on investment for the potential investors. Our goal is to mass-produce mRNA vaccines and to market them for $4 per dose on Advance Purchase Agreements (APA).

Phase 1 Vaccines

Learn More

Normax Pipeline

Phase 2 Vaccines

During Phase 2, Normax plans to develop a new mRNA Vaccine in 100 Days and to build Vax Factories for mRNA Cancer Vaccines in up to 100 Locations. Our goal is to reach a production capacity of 300 million doses per month, on a widely distributed network of Vax Factories.
Our long-term goal is to end the transmission of TB and HIV by 2050.

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.Peter A. Jensen2023-02-03T11:00:00+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax AbstractPeter A. Jensen2022-08-31T11:50:39+00:00

Normax Abstract

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.